H.C. Wainwright analyst Vernon Bernardino lowered the firm’s price target on Can-Fite BioPharma to $18 from $34 and keeps a Buy rating on the shares. The analyst believes Can-Fite’s advancement of piclidenoson and namodenoson into late clinical-stage development is underappreciated, but says the firm’s timeline for piclidenoson’s regulatory approval was too aggressive. As a result, the firm moved its projected approval of piclidenoson in psoriasis to 2028 from 2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CANF:
- Can-Fite shares “Lowe Syndrome Novel Treatment” with Japan orphan drug company
- Can-Fite : Namodenoson inhibits pancreatic cancer growth in pre-clinical studies
- Can-Fite BioPharma files $100M mixed securities shelf
- Can-Fite BioPharma reports 1H revenue $390K vs. $410K for 1H last year
- CANF Earnings Report this Week: Is It a Buy, Ahead of Earnings?